Bicycle Therapeutics plc (50BA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bicycle Therapeutics plc (50BA) has a cash flow conversion efficiency ratio of -0.119x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-65.92 Million ≈ $-77.07 Million USD) by net assets (€554.32 Million ≈ $648.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bicycle Therapeutics plc (50BA) net asset quality to measure how much of total assets are equity-financed.
Bicycle Therapeutics plc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Bicycle Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Bicycle Therapeutics plc (50BA) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Bicycle Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicycle Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
-1.150x |
|
Icelandic Salmon As
OL:ISLAX
|
-0.043x |
|
HomeToGo SE
F:HTG
|
-0.039x |
|
Genova Property Group AB
ST:GPG
|
0.019x |
|
Allpark Empreendimentos Participações e Serviços S.A
SA:ALPK3
|
1.176x |
|
Suryoday Small Finance Bank Limited
NSE:SURYODAY
|
0.001x |
|
Songwon Industrial
KO:004430
|
0.020x |
|
Translational Development Acquisition Corp. Ordinary Shares
NASDAQ:TDAC
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Bicycle Therapeutics plc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bicycle Therapeutics plc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Bicycle Therapeutics plc (50BA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €609.98 Million ≈ $713.13 Million |
€-249.68 Million ≈ $-291.90 Million |
-0.409x | -97.07% |
| 2024-12-31 | €793.06 Million ≈ $927.17 Million |
€-164.72 Million ≈ $-192.58 Million |
-0.208x | -76.51% |
| 2023-12-31 | €370.93 Million ≈ $433.66 Million |
€-43.65 Million ≈ $-51.03 Million |
-0.118x | +63.00% |
| 2022-12-31 | €270.78 Million ≈ $316.57 Million |
€-86.11 Million ≈ $-100.67 Million |
-0.318x | -644.30% |
| 2021-12-31 | €346.25 Million ≈ $404.81 Million |
€-14.79 Million ≈ $-17.30 Million |
-0.043x | +77.07% |
| 2020-12-31 | €95.46 Million ≈ $111.60 Million |
€-17.79 Million ≈ $-20.80 Million |
-0.186x | +39.30% |
| 2019-12-31 | €93.20 Million ≈ $108.96 Million |
€-28.61 Million ≈ $-33.45 Million |
-0.307x | -182.21% |
| 2018-12-31 | €-69.83 Million ≈ $-81.63 Million |
€-26.08 Million ≈ $-30.49 Million |
0.373x | -- |
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more